Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to
higher rates of mortality in those belonging to a lower socioeconomic status due to late …

It has been 12 yr since the publication of the last World Health Organization (WHO)
classification of tumours of the prostate and bladder. During this time, significant new …

Prostate cancer is the second most common malignancy in men worldwide and consists of a
mixture of tumor and non-tumor cell types. To characterize the prostate cancer tumor …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Tumour heterogeneity in primary prostate cancer is a well-established phenomenon.
However, how the subclonal diversity of tumours changes during metastasis and …

There are over 28 million CpG sites in the human genome. Assessing the methylation status
of each of these sites will be required to understand fully the role of DNA methylation in …

Context Given the highly variable behavior and clinical course of prostate cancer (PCa) and
the multiple available treatment options, a personalized approach to oncologic risk …

The discovery of androgen dependence in prostate cancer in 1941 by Huggins and
colleagues has remained the backbone for the treatment of this disease. However, although …

Breast and prostate cancer research to date has largely been predicated on the use of cell
lines in vitro or in vivo. These limitations have led to the development of more clinically …

We report the identification of a molecular signature using the Scano-miR profiling platform
based on the differential expression of circulating microRNAs (miRNA, miR) in serum …